common
cold
common
infecti
diseas
affect
common
cold
viral
upper
respiratori
tract
infect
typic
symptom
includ
nasal
congest
rhinorrhoea
sneez
sore
throat
mani
virus
caus
common
cold
human
rhinovirus
hrv
frequent
averag
adult
two
four
cold
per
mean
durat
symptom
common
cold
report
seven
day
usual
selflimit
howev
common
cold
caus
signific
morbid
substanti
econom
impact
societi
usa
alon
noninfluenza
viral
respiratori
tract
infect
caus
estim
million
lost
workday
million
physician
visit
million
emerg
depart
visit
produc
econom
burden
us
billion
furthermor
hrv
infect
pose
particular
risk
comorbid
asthma
chronic
obstruct
pulmonari
diseas
copd
major
caus
diseas
effect
treatment
identifi
common
cold
current
treatment
mainli
symptomat
mani
cold
remedi
market
exampl
usa
estim
us
billion
spent
overthecount
medic
common
cold
among
treatment
use
zinc
vitamin
c
nasal
decongest
nonsteroid
antiinflammatori
drug
echinacea
antihistamin
antibiot
heat
humidifi
air
evid
effect
mani
inconclus
demonstr
limit
benefit
symptom
hrv
caus
twothird
cold
importantli
hypothesi
test
research
temperaturedepend
antivir
effect
temperatur
hrv
investig
replic
hrv
strain
optim
normal
physiolog
temperatur
upper
studi
report
rais
nasal
mucos
temperatur
may
inhibit
viral
may
treatment
strategi
attenu
sever
durat
common
cold
symptom
forstal
et
al
report
greatest
inhibit
hrv
occur
expos
temperatur
least
one
conti
et
al
report
hrv
replic
suppress
expos
temperatur
rhinothermi
deliveri
heat
humidifi
air
upper
airway
via
nasal
passag
studi
conduct
vivo
deliv
heat
humidifi
air
particip
rang
temperatur
use
varieti
devic
includ
anaesthet
steamvent
nozzl
held
distanc
away
deliveri
system
may
ineffici
inconsist
deliv
humidifi
air
upper
airway
desir
temperatur
recent
cochran
systemat
review
six
rhinothermi
studi
particip
common
cold
treat
heat
humidifi
air
show
harm
benefit
advis
cautiou
interpret
evid
conclud
qualiti
low
review
recommend
doubleblind
randomis
control
trial
rct
need
provid
definit
diagnosi
deriv
viral
cultur
use
uniform
symptom
evid
futur
trial
use
standardis
treatment
modal
effect
consist
rais
temperatur
upper
airway
durat
treatment
technic
difficulti
deliv
heat
humidifi
air
upper
airway
effici
toler
manner
overcom
nasal
high
flow
rhinothermi
rnhf
devic
manufactur
fisher
paykel
healthcar
auckland
new
zealand
devic
consist
deliv
highflow
humidifi
air
heat
upper
airway
devic
well
toler
accept
recent
feasibl
studi
recruit
particip
symptom
common
cold
rct
five
day
rnhf
therapi
vitamin
c
main
patientreport
outcom
measur
modifi
jackson
score
mj
rnhf
therapi
deliv
humidifi
air
lmin
two
hour
daili
compar
vitamin
c
rnhf
treatment
caus
clinic
signific
five
unit
reduct
mj
follow
feasibl
studi
plan
undertak
definit
adequ
power
rct
investig
effect
rnhf
treatment
manag
common
cold
five
day
rnhf
therapi
effect
reduc
symptom
sever
durat
common
cold
five
day
sham
rhinothermi
randomis
singleblind
parallelgroup
trial
compar
five
day
rnhf
therapi
humidifi
air
lmin
two
hour
daili
sham
rhinothermi
therapi
humidifi
air
lmin
minut
daili
treatment
common
cold
plan
recruit
particip
within
hour
onset
specif
symptom
common
cold
particip
randomis
receiv
one
two
possibl
treatment
arm
receiv
treatment
first
five
day
studi
studi
visit
occur
day
one
day
five
followup
phone
call
day
patientreport
outcom
measur
studi
data
collect
record
use
electron
data
captur
tool
redcap
research
electron
data
captur
mj
day
one
collect
investig
part
screen
visit
particip
complet
daili
symptom
diari
includ
daili
mj
remot
enter
data
directli
either
electron
case
report
form
ecrf
redcap
paper
screen
studi
visit
follow
standardis
schedul
procedur
tabl
initi
screen
visit
take
place
medic
research
institut
new
zealand
mrinz
studi
clinic
involv
calcul
symptom
durat
day
one
baselin
mjsassess
presenc
exclus
criteriaobtain
past
medic
surgic
smoke
allergi
medic
historycollect
nasopharyng
specimen
exclud
influenza
b
virusesa
physic
examin
ensur
physic
health
issu
may
exclud
particip
studi
inform
consent
obtain
prior
screen
onlin
supplementari
file
model
screen
particip
inform
sheet
consent
form
prior
enrol
studi
elig
particip
onlin
supplementari
file
model
studi
particip
inform
sheet
consent
form
particip
sign
electron
consent
form
redcap
enrol
particip
ask
refrain
use
overthecount
medic
vitamin
herbal
remedi
specif
common
cold
symptom
relief
use
medic
constitut
reason
withdraw
document
alongsid
collect
particip
data
either
investig
studi
visit
particip
daili
symptom
diari
nasopharyng
specimen
obtain
screen
visit
use
copan
flock
swab
floqswab
specimen
test
presenc
influenza
type
b
viru
nucleic
acid
use
genexpert
xpress
influenzarespiratori
syncyti
viru
rsv
pointofcar
test
cepheid
sunnyval
california
usa
sensit
specif
realtim
pcr
use
genexpert
xpress
influenzarsv
pointofcar
test
rapid
diagnosi
influenza
viru
report
nasopharyng
specimen
obtain
enrol
particip
also
sent
canterburi
health
laboratori
multiplex
respiratori
test
confirm
presenc
absenc
differ
respiratori
pathogen
influenza
viru
influenza
pdm
viru
influenza
b
viru
hrv
human
coronaviru
human
parainfluenza
viru
human
metapneumovirus
ab
human
bocaviru
human
respiratori
syncyti
virus
ab
human
adenoviru
enteroviru
human
parechoviru
mycoplasma
pneumonia
follow
screen
process
elig
particip
enrol
studi
immedi
randomis
one
follow
treatment
arm
rnhf
particip
sham
rhinothermi
particip
permut
block
randomis
method
stratifi
durat
ill
lesser
versu
greater
equal
one
day
use
alloc
particip
either
treatment
arm
computergener
sequenc
suppli
studi
statistician
independ
investig
ecrf
system
conceal
alloc
releas
particip
randomis
outcom
time
randomis
randomis
schedul
access
studi
statistician
ecrf
provid
studi
staff
access
randomis
schedul
two
randomis
treatment
rnhf
humidifi
air
deliv
via
rhinothermi
devic
fisher
paykel
healthcar
lmin
two
hour
daili
five
day
day
one
administ
supervis
investig
day
two
day
five
inclus
particip
selfadminist
treatment
home
particip
encourag
selfadminist
treatment
singl
two
hour
session
day
treatment
howev
unabl
daili
rhinothermi
treatment
split
two
session
aim
particip
complet
total
two
hour
rhinothermi
day
particip
may
also
reduc
flow
lmin
lmin
home
accord
comfort
sham
rhinothermi
humidifi
air
deliv
via
devic
fisher
paykel
healthcar
lmin
minut
daili
five
day
day
one
administ
supervis
investig
day
two
day
five
inclus
particip
selfadminist
treatment
home
particip
encourag
selfadminist
sham
rhinothermi
singl
minut
session
day
treatment
contrast
recent
feasibl
studi
sham
rhinothermi
use
control
rather
vitamin
c
use
sham
rhinothermi
control
arm
provid
advantag
mask
particip
treatment
alloc
control
placebo
effect
associ
use
rhinothermi
devic
rational
sham
devic
set
produc
treatment
unlik
therapeut
effect
respiratori
pathogen
temperaturedepend
replic
temperatur
inhibit
viral
replic
gener
safeti
check
complet
devic
provid
use
particip
also
ask
read
relev
devic
warn
person
sign
date
document
read
understood
intervent
control
devic
automat
record
devic
use
data
electron
adher
rnhf
sham
rhinothermi
treatment
assess
investig
review
data
adher
rnhf
defin
minimum
minut
use
per
day
deliv
two
session
per
day
adher
sham
rhinothermi
defin
minimum
minut
use
per
day
deliv
singl
session
day
one
mj
calcul
part
screen
visit
particip
ask
complet
daili
symptom
diari
onlin
subsequ
day
link
daili
symptom
diari
gener
redcap
sent
particip
via
autom
email
daili
symptom
diari
data
enter
directli
redcap
particip
particip
without
comput
internet
access
provid
paper
version
daili
symptom
diari
use
electron
paper
symptom
diari
figur
particip
document
noncomplet
onlin
symptom
diari
trigger
remind
redcap
particip
return
mrinz
studi
clinic
second
visit
return
devic
complet
toler
questionnair
regard
devic
treatment
new
medic
advers
event
ae
devic
issu
also
review
visit
particip
administ
day
five
treatment
rnhf
sham
rhinothermi
time
attend
encourag
receiv
alloc
treatment
day
five
visit
investig
download
devic
use
data
particip
devic
upload
redcap
particip
receiv
followup
phone
call
final
day
studi
day
review
new
medic
ae
devic
issu
confirm
end
studi
particip
ask
provid
feedback
consid
appropri
studi
reimburs
arrang
sent
statist
analys
use
intentiontotreat
principl
particip
randomis
includ
analysi
primari
comparison
rnhf
treatment
sham
rhinothermi
treatment
primari
outcom
variabl
analys
analysi
covari
ancova
day
one
baselin
mj
covari
interact
analysi
use
assess
evid
differ
treatment
outcom
particip
test
posit
hrv
sensit
analysi
use
assess
evid
interact
adher
primari
outcom
type
error
rate
primari
analysi
p
valu
deviat
origin
statist
plan
describ
justifi
protocol
final
report
appropri
recent
rct
rnhf
compar
vitamin
c
reduct
mj
repres
substanti
clinic
upper
confid
limit
sd
trial
sampl
size
group
allow
detect
differ
unit
power
type
error
rate
feasibl
studi
dropout
rate
zero
howev
even
though
likelihood
dropout
studi
low
order
ensur
studi
remain
adequ
power
allow
dropout
rate
power
calcul
allow
dropout
rate
total
particip
randomis
group
interim
analysi
particip
directli
involv
develop
research
question
outcom
measur
design
studi
studi
protocol
develop
base
previou
similar
studi
exist
medic
literatur
outlin
introduct
review
literatur
indic
public
interest
conduct
research
investig
treatment
common
cold
reduct
symptom
sever
durat
prioriti
individu
common
cold
studi
includ
outcom
measur
investig
effect
rhinothermi
symptom
sever
durat
ill
recent
feasibl
studi
involv
particip
provid
inform
relat
effect
recruit
method
toler
devic
adher
feasibl
studi
shown
rhinothermi
devic
well
howev
consolid
find
assess
treatment
burden
studi
includ
outcom
measur
look
adher
toler
treatment
particip
also
encourag
provid
feedback
rais
concern
regard
aspect
studi
complet
result
studi
submit
public
result
also
dissemin
particip
indic
wish
receiv
particip
elig
monetari
reimburs
complet
studi
standard
agre
amount
decid
cover
expens
associ
particip
studi
particip
elig
reimburs
complet
studi
amount
either
full
agre
amount
complet
studi
entireti
reduc
amount
proport
involv
studi
princip
investig
pi
submit
chang
relev
parti
includ
studi
funder
substanti
amend
origin
approv
document
submit
health
disabl
ethic
committe
ethic
review
studi
recruit
paus
substanti
amend
approv
ethic
committe
protocol
chang
also
submit
australian
new
zealand
clinic
trial
registri
investig
ensur
trial
conduct
accord
principl
declar
helsinki
good
clinic
practic
sponsor
fisher
paykel
healthcar
monitor
studi
accord
procedur
review
seriou
ae
sae
ae
devic
defici
report
studi
sponsor
accord
current
local
nation
advers
event
report
polici
sponsor
manag
devic
defici
report
part
ongo
postmarket
safeti
review
process
sponsor
report
ae
relev
investig
devic
defici
regulatori
author
pi
within
requir
time
period
accord
current
report
requir
data
safeti
monitor
committe
dsmc
appoint
review
sae
expedit
basi
ensur
adequ
studi
safeti
review
enrol
withdraw
ae
everi
month
dsmc
may
recommend
sponsor
studi
termin
howev
final
decis
made
sponsor
pi
correspond
author
full
access
studi
data
final
respons
submit
report
public
pi
also
take
respons
report
result
particip
express
would
like
receiv
studi
result
public
studi
outcom
compris
public
studi
whole
encourag
sponsor
regardless
outcom
sponsor
involv
collect
analysi
interpret
data
prepar
report
decis
submit
public
